Initial Epoprostenol Infusion Rate
Start epoprostenol at 2 ng/kg/min via continuous intravenous infusion through a central venous catheter (temporary peripheral access acceptable until central line established). 1
Dosing Protocol
The FDA-approved initiation protocol is straightforward:
- Starting dose: 2 ng/kg/min
- Titration: Increase by 2 ng/kg/min increments every 15 minutes or longer
- Goal: Continue titration until dose-limiting side effects occur or further increases are not clinically warranted
- If 2 ng/kg/min not tolerated: Use a lower starting dose 1
Dose Escalation During Initial Days
In clinical trials, the typical escalation pattern was:
- Mean starting dose: 2.2 ng/kg/min
- By day 7: Mean dose reached 4.1 ng/kg/min (increased daily)
- By week 12: Mean dose 11.2 ng/kg/min
- Incremental increases averaged 2-3 ng/kg/min every 3 weeks 1
Expert consensus suggests the optimal chronic maintenance dose for most adults on monotherapy ranges between 25-40 ng/kg/min, though this must be individualized 2.
Dose-Limiting Side Effects to Monitor
The most common adverse events that limit dose escalation include:
- Nausea and vomiting
- Hypotension
- Headache
- Abdominal pain
- Flushing
- Respiratory symptoms 1
Critical caveat: If dose-limiting effects occur, decrease the infusion rate by 2 ng/kg/min decrements every 15 minutes until symptoms resolve. Most treatment-limiting events are not serious and may resolve without dosage adjustment 1.
Administration Requirements
- Route: Continuous IV infusion via central venous catheter (peripheral temporarily acceptable)
- Pump requirements: Must deliver in 2 ng/kg/min increments with appropriate alarms
- Filter: Use 0.22 micron in-line filter
- Monitoring: Check standing and supine blood pressure and heart rate for several hours after each dose adjustment 1
Critical Safety Warning
Never abruptly discontinue or make sudden large reductions in epoprostenol infusion rates except in life-threatening situations (unconsciousness, collapse). All dose adjustments should occur under physician direction 1. This medication has a 3-5 minute half-life, making abrupt cessation potentially catastrophic 3.
The evidence supporting this dosing comes directly from FDA labeling 1 and is reinforced by major society guidelines 3, 2, making this the definitive standard of care for epoprostenol initiation in pulmonary arterial hypertension.